J&J: agreement to acquire Intra-Cellular Therapies
(CercleFinance.com) - Johnson & Johnson reports that it has entered into a definitive agreement to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders, for a total net value of approximately $14.
6bn.
The agreement includes Caplyta, an oral treatment approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), both as monotherapy and adjunctive therapy.
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation, as well as a clinical-stage pipeline.
Under the terms of the agreement, J&J will acquire all outstanding shares of Intra-Cellular Therapies at a price of $132 per share in cash. Subject to applicable approvals, the transaction is expected to close later this year.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
6bn.
The agreement includes Caplyta, an oral treatment approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), both as monotherapy and adjunctive therapy.
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation, as well as a clinical-stage pipeline.
Under the terms of the agreement, J&J will acquire all outstanding shares of Intra-Cellular Therapies at a price of $132 per share in cash. Subject to applicable approvals, the transaction is expected to close later this year.
Copyright (c) 2025 CercleFinance.com. All rights reserved.